Tumor News and Research

RSS

Cancer institute offers new tumor monitoring system for radiation therapy patients

A new system that utilizes a precise a GPS-like system to track prostate cancer tumors is now being offered to patients undergoing radiation therapy at Cedars-Sinai's Samuel Oschin Comprehensive Cancer Institute. The monitoring system, called Calypso, allows radiation beams to more precisely target the cancer as it gives real-time positioning information that allows the radiation beams to focus directly on the cancer.

23 Jul 2010

GRB7 gene drives an aggressive form of breast cancer, researchers find

Oregon Health & Science University Knight Cancer Institute researchers found that the GRB7 gene drives an aggressive form of breast cancer and acts independently of the HER-2 gene, known to be a stimulator of breast cancer growth. Isolating the role of this gene could ultimately help fine-tune a patient's treatment and enable physicians to provide a more accurate prognosis.

23 Jul 2010

Circulating aberrant cells increase as non-small cell lung cancer progresses

A novel approach detects genetically abnormal cells in the blood of non-small cell lung cancer patients that match abnormalities found in tumor cells and increase in number with the severity of the disease, a research team led by scientists at The University of Texas MD Anderson Cancer Center report in the journal Clinical Cancer Research.

23 Jul 2010

New technique to detect abnormal cell circulation in non-small lung cancer

Researchers at The University of Texas M. D. Anderson Cancer Center are testing a new technique for identifying circulating genetically abnormal cells, which can lead to poor prognosis, in patients with non-small cell lung cancer.

23 Jul 2010

hBD-3 biomarker helps early stage detection of oral cancer

Detecting oral cancer in its earliest stages can save the lives of the nearly 40,500 people diagnosed annually. But early detection has been difficult. Case Western Reserve University School of Dental Medicine researchers discovered a biomarker, called human beta defensin-3 (hBD-3), which may serve as an early warning. The defensin is present in all oral cancers and associated with the early stages of oral cancer.

23 Jul 2010

Researchers develop laser-induced thermal therapy to treat cancer

A group of researchers from Wake Forest University Baptist Medical Center is developing a way to treat cancer by using lasers to light up tiny nanoparticles and destroy tumors with the ensuing heat. Today at the 52nd Annual Meeting of the American Association of Physicists in Medicine in Philadelphia, they will describe the latest development for this technology: iron-containing Multi-Walled Carbon Nanotubes threads of hollow carbon that are 10 thousand times thinner than a human hair.

22 Jul 2010

Researchers block stress responses in cancer surgery patients

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

22 Jul 2010

GE, MSKCC launch colon cancer study

A team of scientists at GE Global Research, the technology development arm for the GE, has launched a study with Memorial Sloan-Kettering Cancer Center, (MSKCC) one of the world's premier cancer centers, to better understand the early stages of colon cancer. The goal is to yield new insights that improve treatment selection and outcomes for cancer patients in the future.

22 Jul 2010

Researchers receive $780,000 to study estrogen levels, behavior of breast cancer tumors

Researchers at the University of California, San Diego School of Medicine received nearly $780,000 from the Susan G. Komen for the Cure for two studies regarding estrogen levels and the behavior of breast cancer tumors.

22 Jul 2010

Researchers develop new way to reduce radiation dose in CT perfusion procedure

Perfusion CT scanning, an emerging imaging technology, got a bad rap last year when a machine set to incorrect radiation levels overdosed hundreds of people in Los Angeles. In the wake of this incident, researchers at the Mayo Clinic, excited by the technology's promise for diagnosing stroke, cancer, and possibly heart disease, have developed a way to reduce the amount of radiation involved in the procedure -- which, when done properly, already involves very little risk.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Researchers block central pathway for prostate cancer progression

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

21 Jul 2010

Patent application for inexpensive CyPath assay filed by Biomoda

Cancer diagnostics company Biomoda,filed a U.S. patent application on a quantitative method for scoring cells labeled with the CyPath® assay to determine whether cells are dysplastic or carcinomic by measuring the photon emission rate.

21 Jul 2010

Scientists find way to block androgens, halt tumor progression in prostate cancer

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens. Researchers at UT Southwestern Medical Center have found that blocking one of the enzymatic steps that allow the tumor to produce androgens could be the key in halting a tumor's growth.

21 Jul 2010

Hybrid Linac-MR imaging system tracks cancer tumors in real time

Today, at the 52nd Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Philadelphia, a group of researchers from Stanford University will describe the latest developments toward their goal of integrating two existing medical devices -- medical linear accelerators, or "linacs," which produce powerful X-rays for treating cancer, and magnetic resonance imagers (MRIs), which are widely used to image tumors in the human body.

21 Jul 2010

Seattle Genetics, Agensys commence ASG-5ME ADC phase I clinical trial for metastatic pancreatic cancer

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today announced that they have initiated a phase I clinical trial of ASG-5ME for the treatment of metastatic pancreatic cancer. ASG-5ME is an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors.

20 Jul 2010

Frameless radiosurgery can treat most sensitive regions of brain: Study

While four in 10 clinicians use frameless radiosurgery exclusively to treat cranial indications, user data collected at the 5th International Conference of the Novalis Circle, held last month in Munich, Germany, shows that there are still significant opportunities to increase utilization of the effective treatment approach.

20 Jul 2010

ASTRO accepts 4 abstracts on Stereotactic Body Radiation Therapy for NSCLC

The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLC). The clinicians will present their findings during presentations at ASTRO's 52nd Annual Meeting (October 31 - November 4) at the San Diego Convention Center.

From Elekta 20 Jul 2010

New approach to understand different cancer subtypes

An international team led by St. Jude Children's Research Hospital scientists finds unique combinations of cells and mutations lie at the heart of cancer subgroup revealed for the first time in a pediatric brain tumor

20 Jul 2010

CytRx updates on progress in clinical development of bafetinib in three oncology indications

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces progress with its clinical program to evaluate the preliminary efficacy and safety of its drug candidate bafetinib in three oncology indications. The Company has enrolled its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), is reporting rapid advancement toward the initiation of a Phase 2 proof-of-concept trial in advanced prostate cancer, and is on track to begin clinical evaluation later this year in glioblastoma multiforme, a common and aggressive type of primary brain tumor.

20 Jul 2010